Goldman Sachs analyst Corinne Jenkins reiterated an Early-Stage Biotech rating on Fulcrum Therapeutics (NASDAQ: FULC).The analyst comments "PIONEER results presented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE